

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)



(10) International Publication Number

WO 2021/181361 A1

(51) International Patent Classification:

C07D 339/04 (2006.01) A61P 27/12 (2006.01)
A61P 27/02 (2006.01) A61K 31/381 (2006.01)

(21) International Application Number:

PCT/IB2021/052092

(22) International Filing Date:

12 March 2021 (12.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/079271

13 March 2020 (13.03.2020) CN
63/013,836 22 April 2020 (22.04.2020) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BUCHER, Christoph**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **FLUBACHER, Dietmar**; No-
vartis Pharma AG, Postfach, 4002 Basel (CH). **FOUTCH,**
Jeremiah Douglas; Novartis Pharmaceuticals Corporation,
One Health Plaza, East Hanover, New Jersey 07936 (US).
GHOSH, Malay; Novartis Pharmaceuticals Corporation,
One Health Plaza, East Hanover, New Jersey 07936 (US).
KLUGE, Johannes Franz; Novartis Pharma AG, Postfach,
4002 Basel (CH). **LI, Zaixing**; China Novartis Institutes For
Biomedical Research Co., Ltd., 4218 Jinke Road, Pudong
New Area, Shanghai (CN). **MCALISTER, Cale Ry**; No-
vartis Pharmaceuticals Corporation, One Health Plaza, East
Hanover, New Jersey 07936 (US). **WAYKOLE, Lilad-**
har Murlidhar; China Novartis Institutes For Biomedical
Research Co., Ltd., 4218 Jinke Road, Pudong New Area,
Shanghai (CN). **WORTHMANN, Jens Soren**; Novartis
Pharma AG, Postfach, 4002 Basel (CH). **ZHU, Tingying**;
China Novartis Institutes For Biomedical Research Co.,
Ltd., 4218 Jinke Road, Pudong New Area, Shanghai (CN).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME

(57) Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

WO 2021/181361 A1